Pathos AI acquires majority stake in DeuterOncology to advance MET inhibitor DO-2 for cancer treatment.

Pathos AI has acquired a majority stake in DeuterOncology, a Belgian company developing DO-2, a third-generation MET kinase inhibitor targeting MET-altered cancers. Identified through Pathos's AI-driven Foundry platform, DO-2 shows promising clinical results with 100% tumor shrinkage in certain lung cancer patients and a significantly lower rate of side effects compared to competitors. This acquisition highlights Pathos's data-driven approach to drug development, aiming to bring innovative cancer therapies to market more efficiently. The DO-2 program will now be advanced under Pathos's guidance, leveraging continuous AI analysis to optimize clinical development.